| Rachelle Lynn Burleson, CCNS, APRN | |
|
1218 W Willow Rd, Suite A, Enid, OK 73703-2533 | |
| (580) 242-5800 | |
| (580) 242-5881 |
| Full Name | Rachelle Lynn Burleson |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Acute Care |
| Location | 1218 W Willow Rd, Enid, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699064535 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2100X | Clinical Nurse Specialist - Acute Care | 88871 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rachelle Lynn Burleson, CCNS, APRN 1218 W. Willow, Suite A, Enid, OK 73703 Ph: (580) 242-5800 | Rachelle Lynn Burleson, CCNS, APRN 1218 W Willow Rd, Suite A, Enid, OK 73703-2533 Ph: (580) 242-5800 |
News Archive
Asthmatx Inc., today presented positive five-year data from the Asthma Intervention Research Trial, which evaluated the safety of bronchial thermoplasty with the Alair System. The data demonstrated the absence of clinical complications and the maintenance of stable lung function over a five year period post-BT in patients with moderate to severe asthma.
A pioneering method, developed at Chalmers University of Technology, has demonstrated its potential in a large study, showing that metabolic fingerprints from blood samples could render important new knowledge on the connection between food and health.
Banyan Biomarkers, Inc., a pioneer in developing biomarkers for traumatic brain injury (TBI), today announced the publication of the results for the ALERT-TBI study, an international, multicenter clinical trial utilizing the Banyan Brain Trauma Indicator.
An evolutionary analysis of public health data during a major disease outbreak, such as bird flu, E. coli contamination of food or the current Ebola outbreak could help the emergency services plan their response and contain the disease more effectively.
Starpharma Holdings Limited today announced positive results of a clinical trial that achieved all its objectives demonstrating that 3% SPL7013 Gel (VivaGel) was safe and well-tolerated in sexually abstinent women when administered vaginally, twice daily for 14 days.
› Verified 1 days ago
Teresa Jeanne Etter, APRN-CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 3568 Mcclaflin Dr, Enid, OK 73701 Phone: 580-234-7246 Fax: 580-233-2223 |